Citadel Advisors LLC Acquires New Shares in CeriBell (NASDAQ:CBLL)

Citadel Advisors LLC acquired a new stake in shares of CeriBell (NASDAQ:CBLL) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 206,350 shares of the company’s stock, valued at approximately $5,340,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CBLL. Rhumbline Advisers bought a new stake in shares of CeriBell during the 4th quarter valued at $320,000. Bank of New York Mellon Corp bought a new stake in shares of CeriBell during the 4th quarter valued at $628,000. Charles Schwab Investment Management Inc. bought a new stake in shares of CeriBell during the 4th quarter valued at $2,500,000. PNC Financial Services Group Inc. purchased a new position in CeriBell during the fourth quarter worth about $47,000. Finally, Vanguard Group Inc. purchased a new position in CeriBell during the fourth quarter worth about $18,015,000.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 5,700 shares of the company’s stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the transaction, the chief executive officer now directly owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 24,700 shares of company stock worth $372,434. 20.10% of the stock is currently owned by corporate insiders.

CeriBell Trading Up 2.2%

CBLL opened at $17.97 on Friday. The stock has a 50-day moving average price of $17.50 and a 200-day moving average price of $22.35. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analysts’ expectations of $19.30 million. On average, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CBLL has been the subject of several recent analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a research report on Friday, April 4th. They set a “buy” rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell has an average rating of “Buy” and an average price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.